Tela Bio price target lowered to $1 from $1.25 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio (TELA) to $1 from $1.25 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results, which missed its estimate on the topline but slightly outperformed on the operating loss side. The major focus during today’s call was the updated 2026 outlook, in which full-year growth expectations were lowered nearly by half and imply a steep ramp in the latter part of this year, Piper adds.